{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T11:58:09Z","timestamp":1794916689302,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Aging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Plasma p-tau217 and tau positron emission tomography (PET) are strong prognostic biomarkers in Alzheimer\u2019s disease (AD), but their relative performance in predicting future cognitive decline among cognitively unimpaired (CU) individuals is unclear. In a head-to-head comparison study including nine cohorts and 1,474 individuals, we show that plasma p-tau217 and medial temporal lobe tau-PET signal display similar associations with cognitive decline on a global cognitive composite test (\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    <jats:sub>PET<\/jats:sub>\n                    \u2009=\u20090.34 versus\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    <jats:sub>plasma<\/jats:sub>\n                    \u2009=\u20090.33,\n                    <jats:italic>P<\/jats:italic>\n                    <jats:sub>difference<\/jats:sub>\n                    \u2009=\u20090.653) and with progression to mild cognitive impairment (hazard ratio (HR)\n                    <jats:sub>PET<\/jats:sub>\n                    \u2009=\u20091.61 (1.48\u20131.76) versus HR\n                    <jats:sub>plasma<\/jats:sub>\n                    \u2009=\u20091.57 (1.43\u20131.72),\n                    <jats:italic>P<\/jats:italic>\n                    <jats:sub>difference<\/jats:sub>\n                    \u2009=\u20090.322). Combined plasma and PET models were superior to the single-biomarker models (\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u20090.35,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01). Sequential selection using plasma phosphorylated tau at threonine 217 (p-tau217) and then tau-PET reduced the number of participants required for a clinical trial by 94%, compared to a 76% reduction when using plasma p-tau217 alone. Thus, plasma p-tau217 and tau-PET showed similar performance for predicting future cognitive decline in CU individuals, and their sequential use enhances screening efficiency for preclinical AD trials.\n                  <\/jats:p>","DOI":"10.1038\/s43587-025-00835-z","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T22:36:26Z","timestamp":1743201386000},"page":"883-896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-7477","authenticated-orcid":false,"given":"Rik","family":"Ossenkoppele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5210-9230","authenticated-orcid":false,"given":"Gemma","family":"Salvad\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-8378","authenticated-orcid":false,"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Pichet Binette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Bali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0630-772X","authenticated-orcid":false,"given":"Linda","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Therriault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Rahmouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9116-1376","authenticated-orcid":false,"given":"Pedro","family":"Rosa-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M.","family":"Coomans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9956-4233","authenticated-orcid":false,"given":"Elsmarieke","family":"van de Giessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8766-6224","authenticated-orcid":false,"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-0837","authenticated-orcid":false,"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"Jonaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8501-545X","authenticated-orcid":false,"given":"Sterling C.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-0467","authenticated-orcid":false,"given":"Sylvia","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PREVENT-AD Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-0552","authenticated-orcid":false,"given":"Tammie L. S.","family":"Benzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1680-1465","authenticated-orcid":false,"given":"Suzanne E.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7729-1702","authenticated-orcid":false,"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2863-0293","authenticated-orcid":false,"given":"James D.","family":"Doecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8051-0558","authenticated-orcid":false,"given":"Vincent","family":"Dor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0826-4011","authenticated-orcid":false,"given":"Azadeh","family":"Feizpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin L.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3910-2453","authenticated-orcid":false,"given":"Christopher","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Wiste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8178-6601","authenticated-orcid":false,"given":"Ronald C.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-622X","authenticated-orcid":false,"suffix":"Jr.","given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"835_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954\u2013963 (2021).","journal-title":"Nat. Med."},{"key":"835_CR2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaneurol.2022.2379","volume":"79","author":"C Strikwerda-Brown","year":"2022","unstructured":"Strikwerda-Brown, C. et al. Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurol. 79, 975\u2013985 (2022).","journal-title":"JAMA Neurol."},{"key":"835_CR3","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151\u20131162 (2018).","journal-title":"JAMA"},{"key":"835_CR4","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1093\/brain\/awz268","volume":"142","author":"CR Jack","year":"2019","unstructured":"Jack, C. R. et al. The bivariate distribution of amyloid-\u03b2 and tau: relationship with established neurocognitive clinical syndromes. Brain 142, 3230\u20133242 (2019).","journal-title":"Brain"},{"key":"835_CR5","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","volume":"78","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele, R. et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 78, 961\u2013971 (2021).","journal-title":"JAMA Neurol."},{"key":"835_CR6","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1093\/brain\/awaa180","volume":"143","author":"TA Pascoal","year":"2020","unstructured":"Pascoal, T. A. et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain 143, 2818\u20132830 (2020).","journal-title":"Brain"},{"key":"835_CR7","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","volume":"77","author":"A Leuzy","year":"2020","unstructured":"Leuzy, A. et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 77, 955\u2013965 (2020).","journal-title":"JAMA Neurol."},{"key":"835_CR8","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/alz.12356","volume":"17","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele, R. & Hansson, O. Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer\u2019s disease. Alzheimers Dement. 17, 1998\u20132008 (2021).","journal-title":"Alzheimers Dement."},{"key":"835_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson, O., Blennow, K., Zetterberg, H. & Dage, J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat. Aging 3, 506\u2013519 (2023).","journal-title":"Nat. Aging"},{"key":"835_CR10","first-page":"e12307","volume":"14","author":"V Dore","year":"2022","unstructured":"Dore, V. et al. Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer\u2019s continuum. Alzheimers Dement. 14, e12307 (2022).","journal-title":"Alzheimers Dement."},{"key":"835_CR11","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton, N. J. et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat. Med. 28, 2555\u20132562 (2022).","journal-title":"Nat. Med."},{"key":"835_CR12","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist, S. et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat. Med. 27, 1034\u20131042 (2021).","journal-title":"Nat. Med."},{"key":"835_CR13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barthelemy","year":"2020","unstructured":"Barthelemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat. Med. 26, 398\u2013407 (2020).","journal-title":"Nat. Med."},{"key":"835_CR14","first-page":"1797","volume":"28","author":"M Mila-Aloma","year":"2022","unstructured":"Mila-Aloma, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 28, 1797\u20131801 (2022).","journal-title":"Nat. Med."},{"key":"835_CR15","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke, M. M. et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat. Med. 28, 1398\u20131405 (2022).","journal-title":"Nat. Med."},{"key":"835_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen, E. H. et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 20, 739\u2013752 (2021).","journal-title":"Lancet Neurol."},{"key":"835_CR17","doi-asserted-by":"publisher","first-page":"802","DOI":"10.14283\/jpad.2024.122","volume":"11","author":"RA Sperling","year":"2024","unstructured":"Sperling, R. A. et al. Amyloid and tau prediction of cognitive and functional decline in unimpaired older individuals: longitudinal data from the A4 and LEARN studies. J. Prev. Alzheimers Dis. 11, 802\u2013813 (2024).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"835_CR18","doi-asserted-by":"crossref","unstructured":"Palmqvist, S. et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA 332, 1245\u20131257 (2024).","DOI":"10.1001\/jama.2024.13855"},{"key":"835_CR19","doi-asserted-by":"publisher","first-page":"102290","DOI":"10.1016\/j.arr.2024.102290","volume":"96","author":"S Lista","year":"2024","unstructured":"Lista, S. et al. A critical appraisal of blood-based biomarkers for Alzheimer\u2019s disease. Ageing Res. Rev. 96, 102290 (2024).","journal-title":"Ageing Res. Rev."},{"key":"835_CR20","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","volume":"21","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R., van der Kant, R. & Hansson, O. Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726\u2013734 (2022).","journal-title":"Lancet Neurol."},{"key":"835_CR21","doi-asserted-by":"publisher","first-page":"e17123","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvado","year":"2023","unstructured":"Salvado, G. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol. Med. 15, e17123 (2023).","journal-title":"EMBO Mol. Med."},{"key":"835_CR22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault, J. et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 80, 188\u2013199 (2023).","journal-title":"JAMA Neurol."},{"key":"835_CR23","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1002\/alz.12875","volume":"19","author":"R Smith","year":"2023","unstructured":"Smith, R. et al. Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients. Alzheimers Dement. 19, 2497\u20132507 (2023).","journal-title":"Alzheimers Dement."},{"key":"835_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13195-023-01302-w","volume":"15","author":"NS Mundada","year":"2023","unstructured":"Mundada, N. S. et al. Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment. Alzheimers Res. Ther. 15, 157 (2023).","journal-title":"Alzheimers Res. Ther."},{"key":"835_CR25","doi-asserted-by":"publisher","first-page":"828","DOI":"10.14283\/jpad.2023.83","volume":"10","author":"A Feizpour","year":"2023","unstructured":"Feizpour, A. et al. Two-year prognostic utility of plasma p217+tau across the Alzheimer\u2019s continuum. J. Prev. Alzheimers Dis. 10, 828\u2013836 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"835_CR26","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling, R. A. et al. Trial of solanezumab in preclinical Alzheimer\u2019s disease. N. Engl. J. Med. 389, 1096\u20131107 (2023).","journal-title":"N. Engl. J. Med."},{"key":"835_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"835_CR28","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"835_CR29","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. 28, 2381\u20132387 (2022).","journal-title":"Nat. Med."},{"key":"835_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren, N. et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol. 80, 360\u2013369 (2023).","journal-title":"JAMA Neurol."},{"key":"835_CR31","first-page":"668","volume":"3","author":"KV Papp","year":"2017","unstructured":"Papp, K. V., Rentz, D. M., Orlovsky, I., Sperling, R. A. & Mormino, E. C. Optimizing the preclinical Alzheimer\u2019s cognitive composite with semantic processing: the PACC5. Alzheimers Dement. 3, 668\u2013677 (2017).","journal-title":"Alzheimers Dement."},{"key":"835_CR32","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack, C. R. Jr. et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 20, 5143\u20135169 (2024).","journal-title":"Alzheimers Dement."},{"key":"835_CR33","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain 143, 3234\u20133241 (2020).","journal-title":"Brain"},{"key":"835_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-023-02660-3","volume":"147","author":"L Montoliu-Gaya","year":"2023","unstructured":"Montoliu-Gaya, L. et al. Optimal blood tau species for the detection of Alzheimer\u2019s disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study. Acta Neuropathol. 147, 5 (2023).","journal-title":"Acta Neuropathol."},{"key":"835_CR35","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/alz.12245","volume":"17","author":"G Salvado","year":"2021","unstructured":"Salvado, G. et al. Cerebral amyloid-\u03b2 load is associated with neurodegeneration and gliosis: mediation by p-tau and interactions with risk factors early in the Alzheimer\u2019s continuum. Alzheimers Dement. 17, 788\u2013800 (2021).","journal-title":"Alzheimers Dement."},{"key":"835_CR36","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ana.24517","volume":"78","author":"M Marquie","year":"2015","unstructured":"Marquie, M. et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol. 78, 787\u2013800 (2015).","journal-title":"Ann. Neurol."},{"key":"835_CR37","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher, A. S. et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 77, 829\u2013839 (2020).","journal-title":"JAMA Neurol."},{"key":"835_CR38","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jalz.2019.09.079","volume":"16","author":"VJ Lowe","year":"2020","unstructured":"Lowe, V. J. et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 16, 561\u2013571 (2020).","journal-title":"Alzheimers Dement."},{"key":"835_CR39","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1212\/WNL.0000000000002892","volume":"87","author":"H Cho","year":"2016","unstructured":"Cho, H. et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology 87, 375\u2013383 (2016).","journal-title":"Neurology"},{"key":"835_CR40","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.25395","volume":"85","author":"RA Sperling","year":"2019","unstructured":"Sperling, R. A. et al. The impact of amyloid-\u03b2 and tau on prospective cognitive decline in older individuals. Ann. Neurol. 85, 181\u2013193 (2019).","journal-title":"Ann. Neurol."},{"key":"835_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13195-021-00880-x","volume":"13","author":"D Biel","year":"2021","unstructured":"Biel, D. et al. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimers Res. Ther. 13, 137 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"835_CR42","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1001\/jama.2019.7437","volume":"321","author":"CR Jack Jr.","year":"2019","unstructured":"Jack, C. R. Jr. et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA 321, 2316\u20132325 (2019).","journal-title":"JAMA"},{"key":"835_CR43","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1212\/WNL.0000000000006875","volume":"92","author":"R Ossenkoppele","year":"2019","unstructured":"Ossenkoppele, R. et al. Associations between tau, A\u03b2, and cortical thickness with cognition in Alzheimer disease. Neurology 92, e601\u2013e612 (2019).","journal-title":"Neurology"},{"key":"835_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46603-2","volume":"15","author":"WS Brum","year":"2024","unstructured":"Brum, W. S. et al. A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings. Nat. Commun. 15, 2311 (2024).","journal-title":"Nat. Commun."},{"key":"835_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","volume":"81","author":"N Mattsson-Carlgren","year":"2024","unstructured":"Mattsson-Carlgren, N. et al. Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies. JAMA Neurol. 81, 69\u201378 (2024).","journal-title":"JAMA Neurol."},{"key":"835_CR46","first-page":"e12454","volume":"15","author":"VL Villemagne","year":"2023","unstructured":"Villemagne, V. L. et al. CenTauR: toward a universal scale and masks for standardizing tau imaging studies. Alzheimers Dement. 15, e12454 (2023).","journal-title":"Alzheimers Dement."},{"key":"835_CR47","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer, L. A. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 278, 1349\u20131356 (1997).","journal-title":"JAMA"},{"key":"835_CR48","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","volume":"15","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C. C. & Bu, G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat. Rev. Neurol. 15, 501\u2013518 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"835_CR49","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jalz.2018.02.009","volume":"14","author":"N Mattsson","year":"2018","unstructured":"Mattsson, N. et al. Prevalence of the apolipoprotein E \u03b54 allele in amyloid \u03b2 positive subjects across the spectrum of Alzheimer\u2019s disease. Alzheimers Dement. 14, 913\u2013924 (2018).","journal-title":"Alzheimers Dement."},{"key":"835_CR50","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000115751","volume":"30","author":"RO Roberts","year":"2008","unstructured":"Roberts, R. O. et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 30, 58\u201369 (2008).","journal-title":"Neuroepidemiology"},{"key":"835_CR51","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3233\/ADR-210005","volume":"5","author":"C Fowler","year":"2021","unstructured":"Fowler, C. et al. Fifteen years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: progress and observations from 2,359 older adults spanning the spectrum from cognitive normality to Alzheimer\u2019s disease. J. Alzheimers Dis. Rep. 5, 443\u2013468 (2021).","journal-title":"J. Alzheimers Dis. Rep."},{"key":"835_CR52","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13195-018-0390-y","volume":"10","author":"RER Slot","year":"2018","unstructured":"Slot, R. E. R. et al. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimers Res. Ther. 10, 76 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"835_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack Jr.","year":"2017","unstructured":"Jack, C. R. Jr. et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 13, 205\u2013216 (2017).","journal-title":"Alzheimers Dement."},{"key":"835_CR54","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"835_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13195-022-01005-8","volume":"14","author":"C Groot","year":"2022","unstructured":"Groot, C. et al. Diagnostic and prognostic performance to detect Alzheimer\u2019s disease and clinical progression of a novel assay for plasma p-tau217. Alzheimers Res. Ther. 14, 67 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"835_CR56","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue, M. C. et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 71, 961\u2013970 (2014).","journal-title":"JAMA Neurol."},{"key":"835_CR57","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183\u2013194 (2004).","journal-title":"J. Intern. Med."},{"key":"835_CR58","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","volume":"90","author":"RC Petersen","year":"2018","unstructured":"Petersen, R. C. et al. Practice guideline update summary: mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90, 126\u2013135 (2018).","journal-title":"Neurology"}],"container-title":["Nature Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-00835-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-00835-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-00835-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:54:05Z","timestamp":1747738445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-00835-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":58,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["835"],"URL":"https:\/\/doi.org\/10.1038\/s43587-025-00835-z","relation":{},"ISSN":["2662-8465"],"issn-type":[{"value":"2662-8465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.O. has received research support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics. He has given lectures in symposia sponsored by GE Healthcare, received speaker fees from Springer and serves on advisory boards and\/or steering committees for Asceneuron, Bristol Myers Squibb and Biogen. G.S. has received speaker fees from Springer and Adium. S.P. has acquired research support (for the institution) from ki elements (ADDF) and Avid. In the past 2 years, he has received consultancy and\/or speaker fees from BioArctic, Biogen, Esai, Lilly and Roche. Research programs of W.M.v.d.F. have been funded by ZonMw, the NWO, EU-JPND, EU-IHI, Alzheimer Nederland, the Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, the Stichting Dioraphte, Gieskes-Strijbis Fonds, the Stichting Equilibrio, Edwin Bouw Fonds, the Pasman Stichting, the Stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA, Novartis-NL, Life-MI, Avid, Roche, Fujifilm, Eisai and Combinostics. W.M.v.d.F. holds the Pasman chair. W.M.v.d.F. is a recipient of ABOARD, which is a public\u2013private partnership receiving funding from ZonMw (73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP allowance, LSHM20106). W.M.v.d.F. is a recipient of TAP-dementia (\n                      \n                      ), receiving funding from ZonMw (10510032120003) in the context of the Onderzoeksprogramma Dementie, part of the Dutch National Dementia Strategy. TAP-dementia receives cofinancing from Avid Radiopharmaceuticals and Amprion. Gieskes-Strijbis Fonds also contributes to TAP-dementia. W.M.v.d.F. has been an invited speaker at Biogen MA, Danone, Eisai, WebMD Neurology (Medscape), Novo Nordisk, Springer Healthcare and the European Brain Council. W.M.v.d.F. is a consultant to the Oxford Health Policy Forum CIC, Roche, Biogen MA and Eisai. W.M.v.d.F. participated in advisory boards of Biogen MA, Roche and Eli Lilly. W.M.v.d.F. is member of the steering committee of EVOKE and EVOKE+ (Novo Nordisk). All funding is paid to her institution. W.M.v.d.F. is member of the steering committee of PAVE and Think Brain Health. W.M.v.d.F. was an associate editor of\n                      Alzheimer\u2019s Research and Therapy\n                      in 2020 and 2021. W.M.v.d.F. is an associate editor at\n                      Brain\n                      . E.v.d.G. has performed contract research for Heuron and Roche. E.v.d.G. has a consultancy agreement with IXICO and Life Molecular Imaging for reading PET scans. C.E.T. has research contracts with Acumen, ADx Neurosciences, AC Immune, Alamar, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Instant NanoBiosensors, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Toyama and Vivoryon. She is the editor in chief of\n                      Alzheimer\u2019s Research and Therapy\n                      and serves on editorial boards of Medidact Neurologie\/Springer and\n                      Neurology: Neuroimmunology & Neuroinflammation\n                      . She had consultancy and\/or speaker contracts for Eli Lilly, Merck, Novo Nordisk, Olink and Roche. S.E.S. has served as a consultant to Eisai and Novo Nordisk and has received speaker fees from Eli Lilly and Medscape. She has analyzed biomarker data provided by C2N Diagnostics. J.T. has served as a consultant for the Neurotorium educational platform and for Alzheon. P.R.-N. has served on scientific advisory boards and\/or as a consultant for Roche, Novo Nordisk, Eisai and Cerveau Radiopharmaceuticals. C.R. has received research grants from the National Health and Medical Research Council, Enigma Australia, Biogen, Eisai and AbbVie. He is on the scientific advisory board for Enigma\/Meilleur Technologies and has consulted for Prothena, Eisai, Roche and Biogen Australia. R.J.B. has received laboratory research funding from the National Institutes of Health, the Alzheimer\u2019s Association, the BrightFocus Foundation, the Rainwater Foundation, the Association for Frontotemporal Degeneration FTD Biomarkers Initiative, Avid Radiopharmaceuticals, Janssen, the Tau Consortium, Novartis, Centene, the Association for Frontotemporal Degeneration, the Cure Alzheimer\u2019s Fund, Coins for Alzheimer\u2019s Research Trust Fund, the Foundation for Barnes-Jewish Hospital, the Good Ventures Foundation, the DIAN-TU Pharma Consortium, the Tau SILK Consortium (AbbVie, Biogen, Eli Lilly and an anonymous organization), the NfL Consortium (AbbVie, Biogen, Bristol Meyers Squibb, Hoffmann-La Roche) and the Tracy Family SILQ Center; has equity ownership interest in C2N Diagnostics and receives income based on technology licensed by Washington University to C2N Diagnostics; and receives income from C2N Diagnostics for serving on the scientific advisory board. O.H. has acquired research support (for the institution) from Avid Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare and Roche. In the past 2 years, he has received consultancy and\/or speaker fees from AC Immune, ALZpath, BioArctic, Biogen, Bristol Meyers Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. S.C.J. has served in the past 2 years on advisory boards for Enigma Biomedical and ALZpath. The other authors report no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}